Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Biogen Inc (BIIB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 45,572,612
  • Shares Outstanding, K 193,893
  • Annual Sales, $ 13,453 M
  • Annual Income, $ 4,431 M
  • 60-Month Beta 1.01
  • Price/Sales 3.36
  • Price/Cash Flow 7.34
  • Price/Book 3.27

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 24 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate 7.48
  • Number of Estimates 28
  • High Estimate 8.11
  • Low Estimate 6.26
  • Prior Year 5.80
  • Growth Rate Est. (year over year) +28.97%

Price Performance

See More
Period Period Low Period High Performance
1-Month
222.12 +3.15%
on 05/13/19
238.17 -3.80%
on 05/07/19
-1.10 (-0.48%)
since 04/23/19
3-Month
216.12 +6.01%
on 03/25/19
336.57 -31.93%
on 03/04/19
-96.22 (-29.58%)
since 02/22/19
52-Week
216.12 +6.01%
on 03/25/19
388.67 -41.05%
on 07/25/18
-54.64 (-19.26%)
since 05/23/18

Most Recent Stories

More News
Earnings Preview: Veeva (VEEV), Palo Alto Networks (PANW), Workday (WDAY)

Let's look at what investors should expect from some of the more notable tech companies still left to report: Veeva Systems Inc. (VEEV), Workday, Inc. (WDAY), and Palo Alto Networks, Inc. (PANW).

MSFT : 126.18 (-1.17%)
GOOGL : 1,145.34 (-0.91%)
AAPL : 179.66 (-1.71%)
INTC : 44.53 (+1.20%)
VEEV : 140.94 (-2.42%)
LLY : 116.81 (-0.99%)
AMD : 26.36 (-3.83%)
MU : 33.82 (-2.62%)
WDAY : 205.32 (-2.42%)
AMZN : 1,815.48 (-2.38%)
PANW : 215.79 (-5.36%)
BIIB : 229.11 (-2.52%)
3 Tech Stocks for Growth Investors to Buy Right Now

Now it's time to check out three tech stocks that came through our screen today that growth investors might want to consider buying right now.

NFLX : 352.21 (-2.09%)
PYPL : 109.90 (-2.29%)
NVDA : 147.32 (-3.21%)
JPM : 108.64 (-1.97%)
TWTR : 37.19 (-3.60%)
VEEV : 140.94 (-2.42%)
WB : 45.39 (-11.28%)
WDAY : 205.32 (-2.42%)
NOW : 264.79 (-3.15%)
LLY : 116.81 (-0.99%)
FB : 180.87 (-2.40%)
SQ : 63.72 (-4.12%)
CRM : 153.71 (-2.49%)
BIIB : 229.11 (-2.52%)
Top Research Reports for Chubb, Las Vegas Sands & Biogen

Top Research Reports for Chubb, Las Vegas Sands & Biogen

DG : 120.64 (-1.16%)
LVS : 56.97 (-2.76%)
DUK : 88.90 (+1.24%)
CP : 221.86 (-2.26%)
CB : 147.07 (-0.64%)
BIIB : 229.11 (-2.52%)
Biotech Stock Roundup: Label Expansion for CELG's Drugs, Setback for IMGN

Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.

CELG : 95.63 (-0.76%)
ADVM : 9.17 (-0.97%)
VRTX : 173.01 (+0.37%)
IMGN : 1.93 (unch)
BIIB : 229.11 (-2.52%)
Biogen Recommends Stockholders Reject the Below-market Mini-tender Offer by TRC Capital Corporation

Biogen Inc. (Nasdaq: BIIB) today announced that it has received notice of an unsolicited mini-tender offer by TRC Capital Corporation (TRC Capital) to purchase up to 500,000 shares of Biogen's common stock...

BIIB : 229.11 (-2.52%)
Celgene Gets EC Nod for Label Expansion of Revlimid, Imnovid

Celgene (CELG) obtains approval for the label expansion of oncology drugs Revlimid and Imnovid in Europe.

CELG : 95.63 (-0.76%)
RHHBY : 33.7500 (+0.72%)
BMY : 47.30 (-0.92%)
BIIB : 229.11 (-2.52%)
5 Low Price-to-Book Value Stocks for Great Returns

P/B ratio is emerging as a convenient tool for identifying low-priced stocks that have high growth prospects.

BHF : 36.56 (-4.37%)
GIII : 28.95 (-4.42%)
SNX : 93.24 (-3.61%)
DXC : 51.98 (-4.27%)
BIIB : 229.11 (-2.52%)
27.5% Return Seen to Date on SmarTrend Biogen Inc Call (BIIB)

SmarTrend identified a Downtrend for Biogen Inc (NASDAQ:BIIB) on February 7th, 2019 at $316.11. In approximately 3 months, Biogen Inc has returned 27.51% as of today's recent price of $229.14.

BIIB : 229.11 (-2.52%)
Biogen's SPINRAZA(R) (nusinersen) Receives Positive Recommendation from NICE for Funding in the United Kingdom for the Treatment of Infants, Children and Adults with Spinal Muscular Atrophy

Biogen Inc. (Nasdaq: BIIB) today announced that The National Institute for Health and Care Excellence (NICE) in the United Kingdom has recommended funding for SPINRAZA (nusinersen) on the National Health...

IONS : 67.14 (-2.07%)
BIIB : 229.11 (-2.52%)
Dr. Reddy's (RDY) to Report Q4 Earnings: What's in Store?

Dr. Reddy's (RDY) will provide updates on new generic filings and new drug applications, when it reports fourth-quarter fiscal 2019 results.

RDY : 37.69 (-0.40%)
LOGC : 14.81 (-1.46%)
CTST : 5.69 (-3.56%)
BIIB : 229.11 (-2.52%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade BIIB with:

Business Summary

Biogen is a leading biopharmaceutical company engaged in the research, development and marketing of targeted therapies for the treatment of cancer, autoimmune and inflammatory diseases. The company owns industry leading brands for the treatment of multiple sclerosis, next-generation treatments for hemophilia,...

See More

Key Turning Points

2nd Resistance Point 235.74
1st Resistance Point 232.43
Last Price 229.11
1st Support Level 226.59
2nd Support Level 224.06

See More

52-Week High 388.67
Fibonacci 61.8% 322.76
Fibonacci 50% 302.40
Fibonacci 38.2% 282.03
Last Price 229.11
52-Week Low 216.12

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar